Key Points
- Insider sale: Disc Medicine insider Rahul Khara sold 1,649 shares on June 29 at an average price of $75.00, totaling $123,675. After the sale, he still held 52,173 shares valued at about $3.91 million.
- Recent selling trend: Khara also sold 851 shares on June 26 and 7,500 shares on June 18, indicating multiple insider sales over a short period.
- Stock and outlook: Disc Medicine shares were down 1.8% and opened at $73.14, while analysts maintain a Moderate Buy consensus with an average price target of $105.80 despite the company’s recent EPS miss.
Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) COO Jonathan Yen-Wen Yu sold 300 shares of the company's stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $72.50, for a total transaction of $21,750.00. Following the completion of the transaction, the chief operating officer directly owned 54,324 shares in the company, valued at $3,938,490. The trade was a 0.55% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Jonathan Yen-Wen Yu also recently made the following trade(s):
- On Monday, June 22nd, Jonathan Yen-Wen Yu sold 9,700 shares of Disc Medicine stock. The stock was sold at an average price of $72.66, for a total transaction of $704,802.00.
- On Tuesday, June 16th, Jonathan Yen-Wen Yu sold 18,612 shares of Disc Medicine stock. The shares were sold at an average price of $69.19, for a total transaction of $1,287,764.28.
Disc Medicine Price Performance
Disc Medicine stock opened at $73.14 on Wednesday. The company's 50 day simple moving average is $69.01 and its 200-day simple moving average is $70.63. The company has a debt-to-equity ratio of 0.04, a quick ratio of 24.00 and a current ratio of 24.00. Disc Medicine, Inc. has a 1 year low of $40.00 and a 1 year high of $99.50. The company has a market capitalization of $2.79 billion, a price-to-earnings ratio of -11.05 and a beta of 0.93.
Disc Medicine (NASDAQ:IRON - Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($1.65) earnings per share for the quarter, missing analysts' consensus estimates of ($1.62) by ($0.03). As a group, equities research analysts expect that Disc Medicine, Inc. will post -6.74 earnings per share for the current year.
Analyst Upgrades and Downgrades
Several research analysts have recently commented on the company. Wall Street Zen upgraded Disc Medicine from a "strong sell" rating to a "sell" rating in a research report on Saturday, April 25th. Wedbush reiterated an "outperform" rating and issued a $88.00 price objective on shares of Disc Medicine in a report on Wednesday, June 10th. Weiss Ratings reissued a "sell (d-)" rating on shares of Disc Medicine in a research note on Monday, April 20th. Finally, Morgan Stanley raised their target price on Disc Medicine from $80.00 to $85.00 and gave the company an "overweight" rating in a report on Monday, June 15th. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $105.80.
View Our Latest Analysis on Disc Medicine
Institutional Investors Weigh In On Disc Medicine
Hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. boosted its position in Disc Medicine by 110.0% in the 4th quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company's stock valued at $125,557,000 after buying an additional 828,248 shares during the period. BVF Inc. IL acquired a new position in shares of Disc Medicine in the fourth quarter worth $51,616,000. Jennison Associates LLC acquired a new position in shares of Disc Medicine in the fourth quarter worth $42,252,000. Perceptive Advisors LLC purchased a new stake in shares of Disc Medicine during the fourth quarter worth $35,794,000. Finally, RA Capital Management L.P. increased its position in shares of Disc Medicine by 25.3% during the fourth quarter. RA Capital Management L.P. now owns 1,976,132 shares of the company's stock worth $156,925,000 after acquiring an additional 399,026 shares during the period. 83.70% of the stock is currently owned by institutional investors and hedge funds.
About Disc Medicine
(
Get Free Report)
Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.
The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
